Procept Biorobotics Q3 revenue, adjusted EBITDA miss estimates

Overview

• U.S. surgical robotics firm's Q3 revenue grew 18% yr/yr but missed analyst expectations

• Adjusted EBITDA loss for Q3 widened and missed analyst estimates

• Company attributed revenue growth to increased U.S. handpiece and system sales and international revenue

Outlook

• Company reiterates 2026 revenue guidance of $390 mln to $410 mln

• Company maintains 2026 U.S. procedure volume outlook at 54,000-56,000

• Company expects 2026 gross margin of about 65%

Result Drivers

• PROCEDURE GROWTH - U.S. procedure volume rose 22% yr/yr, supporting higher handpiece and consumable revenue

• HANDPIECE PRICING - Average selling price for handpieces increased 12% yr/yr, contributing to revenue growth

• INTERNATIONAL SALES - International revenue grew 32% yr/yr, driven by higher system and consumable sales outside the U.S.

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for PROCEPT BioRobotics Corporation is $22.00, about 9.1% above its November 3 closing price of $20.17

Reuters Recommended Reads

• Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

• Nov 2 - SI-BONE Q3 revenue rises 14.5%, slightly beats estimates

• Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)